Abstract
The aim of this study was to identify the expression of prostate-specific membrane antigen (PSMA) and analyze the correlation between PSMA with clinical characteristics in patients with pancreatic cancer. The expression of PSMA protein and mRNA was detected by immunohistochemistry and real-time quantitative polymerase chain reaction in pancreatic cancer tissues, pancreatic intraepithelial neoplasia or normal pancreatic tissues, respectively. And clinical characteristics and prognosis of patients were investigated. PSMA was expressed in pancreatic cancer cells, both in protein and mRNA levels. Moreover, the PSMA levels were associated with the prognosis of patients with pancreatic ductal adenocarcinoma. The overall survival time of pancreatic cancer patients with high expression of PSMA was significantly shorter than that of the low ones. Moreover, the PSMA levels were correlated with clinicopathological features including the histological grade and pathological tumor-node-metastasis stage. PSMA is involved in the carcinogenesis of pancreatic cancer, and it might serve as a potential therapeutic target for pancreatic cancer.
Similar content being viewed by others
Abbreviations
- PSMA:
-
Prostate-specific membrane antigen
- cDNA:
-
Complementary DNA
- TfR:
-
Transferrin receptor
- pTNM:
-
Pathological tumor-node-metastasis
- RT-PCR:
-
Real-time quantitative-PCR
- PDAC:
-
Pancreatic ductal adenocarcinoma
References
Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.
Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.
Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.
Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977–85.
Wang W, Mo ZN. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 2010;16(6):547–51.
Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int. 2009;104(7):915–8.
Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.
Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy. 2009;3:471–81.
Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012;2012:973820.
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.
Ren H, Zhao H, Wang T, Yang Y, Han Z, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol. 2006;120(2):205–11.
McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin N Am J. 2009;23(6):1163–75.
Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2(3):182–90.
Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–9.
Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31(2):144–54.
Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate. 2012;72(14):1532–41.
Acknowledgments
National Natural Science Foundation of China (Grant Nos. 81302082, 81272685, 31301151, 81172355); Doctoral Fund of Ministry of Education of China (Grant No. 20101202110002); Key program of Natural Science Foundation of Tianjin (Grant Nos. 09JCZDJC17100, 11JCZDJC18400); major anticancer Technologies R&D Program of Tianjin (Grant No. 12ZCDZSY16700); project of Tianjin Educational Commission (Grant No. 20100123).
Conflict of interest
The authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
He Ren and Huan Zhang have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ren, H., Zhang, H., Wang, X. et al. Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol 31, 857 (2014). https://doi.org/10.1007/s12032-014-0857-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0857-z